Abolis Biotechnologies, a company that specializes in industrial solutions using microorganisms, has received a €35 million investment from a consortium of international investors. The funding will be used to expand the company’s operations globally, accelerate its research and development efforts, and bring innovative biomanufacturing and microbiome solutions to the market.
The consortium of investors includes Evonik Venture Capital, L’Oréal’s venture capital fund BOLD, and several impact-focused funds, including DeepTech & Climate Fonds, Clay Capital, Icos Capital, and Liberset.
The investment is accompanied by a new strategic partnership between Abolis, L’Oréal, and Evonik to bring selected innovations to market across various industries, including healthcare, cosmetics, and chemicals. The partnership will enable the companies to collaborate on innovation projects from development to market launch.
Abolis Biotechnologies supports chemical companies and industries in their transition to a more sustainable production model by using microorganisms to produce biobased equivalent or innovative products.
The company’s CEO, Cyrille Pauthenier, stated that the investment will enable Abolis to continue its growth trajectory and strengthen its position as a European leader in biomanufacturing and microbiome solutions.
The investors highlighted the potential of Abolis to create a more sustainable future across various industries, including beauty. They also expressed their commitment to supporting the company’s continued growth and success.
The company’s focus on sustainable biotechnology aligns with the goals of its investors, who are committed to supporting innovative solutions that benefit both human health and the environment.
